Compare Fubotv Inc (FUBO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Novartis AG — how do they compare? Fubotv Inc trades at $9.7 (market cap $1.06B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 278.7× Fubotv Inc's market cap, and Novartis AG pays a 3.07% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals.
| FUBO | NVS | |
|---|---|---|
Market Cap | $1.06B | $295.37B |
Sector | Technology | Health |
52-Week High | $54.72 | $168.62 |
52-Week Low | $8.09 | $119.31 |
Enterprise Value | $1.23B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.36, up 1.08% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growing to $1.62B in 2024 and projected net income turning positive at $123M for 2025. Recent CEO transition to former Disney executive Alisa Bowen and partnerships with major media companies signal strategic repositioning.
While valuation metrics appear attractive with P/E of 2.53 and P/S of 0.19, the stock faces execution risks in achieving profitability targets. Analyst consensus is mixed with 46.7% buy ratings and $15.33 price target, representing significant upside potential if the company can deliver on its EBITDA growth roadmap.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
